Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19

Purpose To study the effect of interferon-α2 auto-antibodies (IFN-α2 Abs) on clinical and virological outcomes in critically ill COVID-19 patients and the risk of IFN-α2 Abs transfer during convalescent plasma treatment. Methods Sera from healthy controls, cases of COVID-19, and other respiratory il...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical immunology Jg. 42; H. 2; S. 232 - 239
Hauptverfasser:	Raadsen, Matthijs P., Gharbharan, Arvind, Jordans, Carlijn C. E., Mykytyn, Anna Z., Lamers, Mart M., van den Doel, Petra B., Endeman, Henrik, van den Akker, Johannes P. C., GeurtsvanKessel, Corine H., Koopmans, Marion P. G., Rokx, Casper, Goeijenbier, Marco, van Gorp, Eric C. M., Rijnders, Bart J. A., Haagmans, Bart L.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	New York Springer US 01.02.2022 Springer Nature B.V
Schlagworte:	Adult Aged Antibodies, Neutralizing - immunology Antibodies, Viral - immunology Antiviral Agents - immunology Autoantibodies Autoantibodies - immunology Biomedical and Life Sciences Biomedicine Blood Component Transfusion - methods Coronaviruses COVID-19 COVID-19 - immunology COVID-19 - therapy COVID-19 Serotherapy Critical Illness Enzyme-linked immunosorbent assay Female Humans Immunization, Passive - methods Immunoglobulin G - immunology Immunology Infectious Diseases Interferon Interferon alpha-2 - immunology Internal Medicine Male Medical Microbiology Middle Aged Original Original Article Patients Plasma Plasma - immunology Respiratory diseases Respiratory tract SARS-CoV-2 - immunology COVID-19 SARS-CoV-2 Convalescent plasma Auto-antibodies Interferon alpha
ISSN:	0271-9142, 1573-2592, 1573-2592
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Purpose To study the effect of interferon-α2 auto-antibodies (IFN-α2 Abs) on clinical and virological outcomes in critically ill COVID-19 patients and the risk of IFN-α2 Abs transfer during convalescent plasma treatment. Methods Sera from healthy controls, cases of COVID-19, and other respiratory illness were tested for IFN-α2 Abs by ELISA and a pseudo virus–based neutralization assay. The effects of disease severity, sex, and age on the risk of having neutralizing IFN-α2 Abs were determined. Longitudinal analyses were performed to determine association between IFN-α2 Abs and survival and viral load and whether serum IFN-α2 Abs appeared after convalescent plasma transfusion. Results IFN-α2 neutralizing sera were found only in COVID-19 patients, with proportions increasing with disease severity and age. In the acute stage of COVID-19, all sera from patients with ELISA-detected IFN-α2 Abs (13/164, 7.9%) neutralized levels of IFN-α2 exceeding physiological concentrations found in human plasma and this was associated with delayed viral clearance. Convalescent plasma donors that were anti-IFN-α2 ELISA positive (3/118, 2.5%) did not neutralize the same levels of IFN-α2. Neutralizing serum IFN-α2 Abs were associated with delayed viral clearance from the respiratory tract. Conclusions IFN-α2 Abs were detected by ELISA and neutralization assay in COVID-19 patients, but not in ICU patients with other respiratory illnesses. The presence of neutralizing IFN-α2 Abs in critically ill COVID-19 is associated with delayed viral clearance. IFN-α2 Abs in COVID-19 convalescent plasma donors were not neutralizing in the conditions tested.
AbstractList	To study the effect of interferon-α2 auto-antibodies (IFN-α2 Abs) on clinical and virological outcomes in critically ill COVID-19 patients and the risk of IFN-α2 Abs transfer during convalescent plasma treatment. Sera from healthy controls, cases of COVID-19, and other respiratory illness were tested for IFN-α2 Abs by ELISA and a pseudo virus-based neutralization assay. The effects of disease severity, sex, and age on the risk of having neutralizing IFN-α2 Abs were determined. Longitudinal analyses were performed to determine association between IFN-α2 Abs and survival and viral load and whether serum IFN-α2 Abs appeared after convalescent plasma transfusion. IFN-α2 neutralizing sera were found only in COVID-19 patients, with proportions increasing with disease severity and age. In the acute stage of COVID-19, all sera from patients with ELISA-detected IFN-α2 Abs (13/164, 7.9%) neutralized levels of IFN-α2 exceeding physiological concentrations found in human plasma and this was associated with delayed viral clearance. Convalescent plasma donors that were anti-IFN-α2 ELISA positive (3/118, 2.5%) did not neutralize the same levels of IFN-α2. Neutralizing serum IFN-α2 Abs were associated with delayed viral clearance from the respiratory tract. IFN-α2 Abs were detected by ELISA and neutralization assay in COVID-19 patients, but not in ICU patients with other respiratory illnesses. The presence of neutralizing IFN-α2 Abs in critically ill COVID-19 is associated with delayed viral clearance. IFN-α2 Abs in COVID-19 convalescent plasma donors were not neutralizing in the conditions tested. Abstract PurposeTo study the effect of interferon-α2 auto-antibodies (IFN-α2 Abs) on clinical and virological outcomes in critically ill COVID-19 patients and the risk of IFN-α2 Abs transfer during convalescent plasma treatment.MethodsSera from healthy controls, cases of COVID-19, and other respiratory illness were tested for IFN-α2 Abs by ELISA and a pseudo virus–based neutralization assay. The effects of disease severity, sex, and age on the risk of having neutralizing IFN-α2 Abs were determined. Longitudinal analyses were performed to determine association between IFN-α2 Abs and survival and viral load and whether serum IFN-α2 Abs appeared after convalescent plasma transfusion.ResultsIFN-α2 neutralizing sera were found only in COVID-19 patients, with proportions increasing with disease severity and age. In the acute stage of COVID-19, all sera from patients with ELISA-detected IFN-α2 Abs (13/164, 7.9%) neutralized levels of IFN-α2 exceeding physiological concentrations found in human plasma and this was associated with delayed viral clearance. Convalescent plasma donors that were anti-IFN-α2 ELISA positive (3/118, 2.5%) did not neutralize the same levels of IFN-α2. Neutralizing serum IFN-α2 Abs were associated with delayed viral clearance from the respiratory tract.ConclusionsIFN-α2 Abs were detected by ELISA and neutralization assay in COVID-19 patients, but not in ICU patients with other respiratory illnesses. The presence of neutralizing IFN-α2 Abs in critically ill COVID-19 is associated with delayed viral clearance. IFN-α2 Abs in COVID-19 convalescent plasma donors were not neutralizing in the conditions tested. To study the effect of interferon-α2 auto-antibodies (IFN-α2 Abs) on clinical and virological outcomes in critically ill COVID-19 patients and the risk of IFN-α2 Abs transfer during convalescent plasma treatment.PURPOSETo study the effect of interferon-α2 auto-antibodies (IFN-α2 Abs) on clinical and virological outcomes in critically ill COVID-19 patients and the risk of IFN-α2 Abs transfer during convalescent plasma treatment.Sera from healthy controls, cases of COVID-19, and other respiratory illness were tested for IFN-α2 Abs by ELISA and a pseudo virus-based neutralization assay. The effects of disease severity, sex, and age on the risk of having neutralizing IFN-α2 Abs were determined. Longitudinal analyses were performed to determine association between IFN-α2 Abs and survival and viral load and whether serum IFN-α2 Abs appeared after convalescent plasma transfusion.METHODSSera from healthy controls, cases of COVID-19, and other respiratory illness were tested for IFN-α2 Abs by ELISA and a pseudo virus-based neutralization assay. The effects of disease severity, sex, and age on the risk of having neutralizing IFN-α2 Abs were determined. Longitudinal analyses were performed to determine association between IFN-α2 Abs and survival and viral load and whether serum IFN-α2 Abs appeared after convalescent plasma transfusion.IFN-α2 neutralizing sera were found only in COVID-19 patients, with proportions increasing with disease severity and age. In the acute stage of COVID-19, all sera from patients with ELISA-detected IFN-α2 Abs (13/164, 7.9%) neutralized levels of IFN-α2 exceeding physiological concentrations found in human plasma and this was associated with delayed viral clearance. Convalescent plasma donors that were anti-IFN-α2 ELISA positive (3/118, 2.5%) did not neutralize the same levels of IFN-α2. Neutralizing serum IFN-α2 Abs were associated with delayed viral clearance from the respiratory tract.RESULTSIFN-α2 neutralizing sera were found only in COVID-19 patients, with proportions increasing with disease severity and age. In the acute stage of COVID-19, all sera from patients with ELISA-detected IFN-α2 Abs (13/164, 7.9%) neutralized levels of IFN-α2 exceeding physiological concentrations found in human plasma and this was associated with delayed viral clearance. Convalescent plasma donors that were anti-IFN-α2 ELISA positive (3/118, 2.5%) did not neutralize the same levels of IFN-α2. Neutralizing serum IFN-α2 Abs were associated with delayed viral clearance from the respiratory tract.IFN-α2 Abs were detected by ELISA and neutralization assay in COVID-19 patients, but not in ICU patients with other respiratory illnesses. The presence of neutralizing IFN-α2 Abs in critically ill COVID-19 is associated with delayed viral clearance. IFN-α2 Abs in COVID-19 convalescent plasma donors were not neutralizing in the conditions tested.CONCLUSIONSIFN-α2 Abs were detected by ELISA and neutralization assay in COVID-19 patients, but not in ICU patients with other respiratory illnesses. The presence of neutralizing IFN-α2 Abs in critically ill COVID-19 is associated with delayed viral clearance. IFN-α2 Abs in COVID-19 convalescent plasma donors were not neutralizing in the conditions tested. Purpose To study the effect of interferon-α2 auto-antibodies (IFN-α2 Abs) on clinical and virological outcomes in critically ill COVID-19 patients and the risk of IFN-α2 Abs transfer during convalescent plasma treatment. Methods Sera from healthy controls, cases of COVID-19, and other respiratory illness were tested for IFN-α2 Abs by ELISA and a pseudo virus–based neutralization assay. The effects of disease severity, sex, and age on the risk of having neutralizing IFN-α2 Abs were determined. Longitudinal analyses were performed to determine association between IFN-α2 Abs and survival and viral load and whether serum IFN-α2 Abs appeared after convalescent plasma transfusion. Results IFN-α2 neutralizing sera were found only in COVID-19 patients, with proportions increasing with disease severity and age. In the acute stage of COVID-19, all sera from patients with ELISA-detected IFN-α2 Abs (13/164, 7.9%) neutralized levels of IFN-α2 exceeding physiological concentrations found in human plasma and this was associated with delayed viral clearance. Convalescent plasma donors that were anti-IFN-α2 ELISA positive (3/118, 2.5%) did not neutralize the same levels of IFN-α2. Neutralizing serum IFN-α2 Abs were associated with delayed viral clearance from the respiratory tract. Conclusions IFN-α2 Abs were detected by ELISA and neutralization assay in COVID-19 patients, but not in ICU patients with other respiratory illnesses. The presence of neutralizing IFN-α2 Abs in critically ill COVID-19 is associated with delayed viral clearance. IFN-α2 Abs in COVID-19 convalescent plasma donors were not neutralizing in the conditions tested.
Author	Lamers, Mart M. GeurtsvanKessel, Corine H. Endeman, Henrik Raadsen, Matthijs P. Jordans, Carlijn C. E. van den Doel, Petra B. van den Akker, Johannes P. C. Rokx, Casper Goeijenbier, Marco Koopmans, Marion P. G. Mykytyn, Anna Z. Haagmans, Bart L. Rijnders, Bart J. A. van Gorp, Eric C. M. Gharbharan, Arvind
Author_xml	– sequence: 1 givenname: Matthijs P. orcidid: 0000-0002-3774-8165 surname: Raadsen fullname: Raadsen, Matthijs P. organization: Viroscience Department, Erasmus MC – sequence: 2 givenname: Arvind surname: Gharbharan fullname: Gharbharan, Arvind organization: Department of Medical Microbiology and Infectious Diseases, Erasmus MC – sequence: 3 givenname: Carlijn C. E. surname: Jordans fullname: Jordans, Carlijn C. E. organization: Department of Medical Microbiology and Infectious Diseases, Erasmus MC – sequence: 4 givenname: Anna Z. surname: Mykytyn fullname: Mykytyn, Anna Z. organization: Viroscience Department, Erasmus MC – sequence: 5 givenname: Mart M. surname: Lamers fullname: Lamers, Mart M. organization: Viroscience Department, Erasmus MC – sequence: 6 givenname: Petra B. surname: van den Doel fullname: van den Doel, Petra B. organization: Viroscience Department, Erasmus MC – sequence: 7 givenname: Henrik surname: Endeman fullname: Endeman, Henrik organization: Intensive Care Department, Erasmus MC – sequence: 8 givenname: Johannes P. C. surname: van den Akker fullname: van den Akker, Johannes P. C. organization: Intensive Care Department, Erasmus MC – sequence: 9 givenname: Corine H. surname: GeurtsvanKessel fullname: GeurtsvanKessel, Corine H. organization: Viroscience Department, Erasmus MC – sequence: 10 givenname: Marion P. G. surname: Koopmans fullname: Koopmans, Marion P. G. organization: Viroscience Department, Erasmus MC – sequence: 11 givenname: Casper surname: Rokx fullname: Rokx, Casper organization: Department of Medical Microbiology and Infectious Diseases, Erasmus MC – sequence: 12 givenname: Marco surname: Goeijenbier fullname: Goeijenbier, Marco organization: Viroscience Department, Erasmus MC, Intensive Care Department, Erasmus MC – sequence: 13 givenname: Eric C. M. surname: van Gorp fullname: van Gorp, Eric C. M. organization: Viroscience Department, Erasmus MC – sequence: 14 givenname: Bart J. A. surname: Rijnders fullname: Rijnders, Bart J. A. organization: Department of Medical Microbiology and Infectious Diseases, Erasmus MC – sequence: 15 givenname: Bart L. surname: Haagmans fullname: Haagmans, Bart L. email: b.haagmans@erasmusmc.nl organization: Viroscience Department, Erasmus MC
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/34767118$$D View this record in MEDLINE/PubMed
BookMark	eNp9kctuFDEQRS0URCaBH2CBWmLDxlBlu_3YIEXDa1CksAhsLafbnTjqsQe7O1I-ix_JN8XDJDyyyKoWde7VrboHZC-m6Al5ifAWAdS7gqBVS4EhBUSpKX9CFtgqTllr2B5ZAFNIDQq2Tw5KuQQALln7jOxzoaRC1AvydRUnnwefU6Q3v1hzNE-JujiFs9QHX5oQm2WKV270pfNxar6Nrqxdc3rhs9tcN0PKzfLkx-oDRfOcPB3cWPyLu3lIvn_6eLr8Qo9PPq-WR8e0awVMVMHAmRp6YTwHZ9gggIlWmh6Y9MYI2UnnRWegQyV6KQU41va95qaXejDID8n7ne9mPlv7fhsru9Fucli7fG2TC_b_TQwX9jxdWd1qqTlUgzd3Bjn9nH2Z7DrU68bRRZ_mYuv3lDDAgFX09QP0Ms051vMsk0wiCgRTqVf_JvoT5f7NFdA7oMuplOwH24XJTSFtA4bRIthto3bXqK2N2t-NWl6l7IH03v1REd-JSoXjuc9_Yz-iugXEGbFI
CitedBy_id	crossref_primary_10_1016_j_nmni_2024_101525 crossref_primary_10_1084_jem_20220258 crossref_primary_10_1016_j_ebiom_2022_104414 crossref_primary_10_1093_cei_uxae062 crossref_primary_10_1016_j_jaci_2022_11_010 crossref_primary_10_3390_cells11142198 crossref_primary_10_1186_s12879_022_07560_7 crossref_primary_10_1016_j_jiph_2025_102722 crossref_primary_10_1111_imr_13113 crossref_primary_10_1007_s10875_023_01512_9 crossref_primary_10_1084_jem_20231353 crossref_primary_10_1172_JCI166283 crossref_primary_10_1073_pnas_2200413119 crossref_primary_10_1084_jem_20231152 crossref_primary_10_1007_s10875_024_01839_x crossref_primary_10_1073_pnas_2402983121 crossref_primary_10_3390_v15051215 crossref_primary_10_1080_25785826_2025_2488553 crossref_primary_10_1146_annurev_biodatasci_020222_021705 crossref_primary_10_29235_1561_8323_2025_69_4_303_313 crossref_primary_10_1186_s13613_022_01095_5 crossref_primary_10_1038_s41586_022_04447_0 crossref_primary_10_1016_j_coi_2024_102427 crossref_primary_10_1146_annurev_immunol_101921_050835 crossref_primary_10_1016_j_hrtlng_2024_03_005 crossref_primary_10_1016_j_cell_2022_07_004 crossref_primary_10_1111_imr_13304 crossref_primary_10_3390_v14061141 crossref_primary_10_1126_sciimmunol_abp8966 crossref_primary_10_1093_cei_uxad119 crossref_primary_10_1084_jem_20240942 crossref_primary_10_1080_23744235_2025_2483339 crossref_primary_10_1084_jem_20220514 crossref_primary_10_1136_ard_2022_222549
Cites_doi	10.1111/bjh.13459 10.1056/NEJMoa2031304 10.1126/science.abc6027 10.1111/cts.12805 10.1126/science.abd4570 10.1056/NEJMoa2035002 10.1007/s10875-021-01060-0 10.1038/s41467-020-17317-y 10.1038/s43856-021-00006-2 10.1016/S1473-3099(20)30483-7 10.1136/bmj.m1966 10.1016/S0140-6736(20)30183-5 10.1111/j.1537-2995.2010.02715.x 10.3201/eid2607.200841 10.1056/NEJMoa2029849 10.1007/s00134-020-06062-x 10.7554/eLife.64508 10.1126/science.abd4585 10.1084/jem.20202486 10.1126/sciimmunol.abl4340 10.1101/2020.12.10.20247205 10.21203/rs.3.rs-105265/v1 10.1007/s00134-021-06392-4
ContentType	Journal Article
Copyright	The Author(s) 2021 2021. The Author(s). The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: The Author(s) 2021 – notice: 2021. The Author(s). – notice: The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7X7 7XB 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM
DOI	10.1007/s10875-021-01168-3
DatabaseName	Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection ProQuest Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Biological Science Database ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE ProQuest Central Student MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1573-2592
EndPage	239
ExternalDocumentID	PMC8586830 34767118 10_1007_s10875_021_01168_3
Genre	Journal Article
GroupedDBID	--- -4W -56 -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 199 1N0 1SB 2.D 203 28- 29K 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 3SX 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67N 67Z 6NX 78A 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AAJSJ AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABBBX ABBXA ABDZT ABECU ABFTV ABHLI ABHQN ABJNI ABJOX ABKCH ABKTR ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTHY ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHVE ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACULB ACZOJ ADBBV ADHHG ADHIR ADIMF ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADYPR ADZKW AEBTG AEFIE AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFFNX AFGCZ AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBNVY BBWZM BDATZ BENPR BGNMA BHPHI BPHCQ BSONS BVXVI C6C CAG CCPQU COF CS3 CSCUP D-I DDRTE DL5 DNIVK DPUIP EBD EBLON EBS EIOEI EJD EMOBN EN4 EPAXT ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GXS H13 HCIFZ HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH L7B LAK LK8 LLZTM M1P M4Y M7P MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI RNS ROL RPX RRX RSV RZC RZE RZK S16 S1Z S26 S27 S28 S3A S3B SAP SBL SBY SCLPG SDH SDM SHX SISQX SJYHP SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZN T13 T16 TEORI TSG TSK TSV TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW VVN W23 W48 WJK WK6 WK8 Y6R YLTOR Z45 Z7U Z82 Z87 Z8O Z8V Z91 ZGI ZMTXR ZOVNA ~EX ~KM AAPKM AAYXX ABBRH ABDBE ABEEZ ABFSG ACSTC ADHKG AEZWR AFDZB AFFHD AFGXO AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY PQGLB CGR CUY CVF ECM EIF NPM 7T5 7XB 8FK AZQEC DWQXO GNUQQ H94 K9. PKEHL PQEST PQUKI PRINS 7X8 5PM
ID	FETCH-LOGICAL-c540t-70f327fd49e30a92f4024569d026e9946c6ae4c90c174d6640a25dd839d68f913
IEDL.DBID	RSV
ISICitedReferencesCount	37
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000717931900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0271-9142 1573-2592
IngestDate	Tue Nov 04 01:44:31 EST 2025 Sun Nov 09 11:55:15 EST 2025 Fri Oct 03 11:00:08 EDT 2025 Mon Jul 21 05:45:31 EDT 2025 Tue Nov 18 20:48:38 EST 2025 Sat Nov 29 05:00:09 EST 2025 Fri Feb 21 02:47:42 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	2
Keywords	COVID-19 SARS-CoV-2 Convalescent plasma Auto-antibodies Interferon alpha
Language	English
License	2021. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c540t-70f327fd49e30a92f4024569d026e9946c6ae4c90c174d6640a25dd839d68f913
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0002-3774-8165
OpenAccessLink	https://link.springer.com/10.1007/s10875-021-01168-3
PMID	34767118
PQID	2626114109
PQPubID	37573
PageCount	8
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_8586830 proquest_miscellaneous_2597490202 proquest_journals_2626114109 pubmed_primary_34767118 crossref_citationtrail_10_1007_s10875_021_01168_3 crossref_primary_10_1007_s10875_021_01168_3 springer_journals_10_1007_s10875_021_01168_3
PublicationCentury	2000
PublicationDate	2022-02-01
PublicationDateYYYYMMDD	2022-02-01
PublicationDate_xml	– month: 02 year: 2022 text: 2022-02-01 day: 01
PublicationDecade	2020
PublicationPlace	New York
PublicationPlace_xml	– name: New York – name: Netherlands
PublicationSubtitle	International Journal of Inborn Errors of Immunity and Related Diseases
PublicationTitle	Journal of clinical immunology
PublicationTitleAbbrev	J Clin Immunol
PublicationTitleAlternate	J Clin Immunol
PublicationYear	2022
Publisher	Springer US Springer Nature B.V
Publisher_xml	– name: Springer US – name: Springer Nature B.V
References	Jun, Nirenberg, Weinberger, Sharma, Pujadas, Cordon-Cardo (CR21) 2021; 1 Vazquez, Bastard, Kelly, Gervais, Norris, Dumont (CR7) 2021; 41 CR6 Chen, Nirula, Heller, Gottlieb, Boscia, Morris (CR11) 2020; 384 Peters, Van Stein, Vlaar (CR12) 2015; 170 Zhou, Han, Chen, Hou, Hua, He (CR19) 2020; 13 CR18 Middelburg, Van Stein, Zupanska, Uhrynowska, Gajic, Muñiz-Diaz (CR13) 2010; 50 CR9 CR15 CR23 CR22 CR20 Hadjadj, Yatim, Barnabei, Corneau, Boussier, Smith (CR4) 2020; 369 Marshall, Murthy, Diaz, Adhikari, Angus, Arabi (CR14) 2020; 20 Weinreich, Sivapalasingam, Norton, Ali, Gao, Bhore (CR10) 2020; 384 GeurtsvanKessel, Okba, Igloi, Bogers, Embregts, Laksono (CR16) 2020; 11 Huang, Wang, Li, Ren, Zhao, Hu (CR1) 2020; 395 Simonovich, Burgos Pratx, Scibona, Beruto, Vallone, Vázquez (CR8) 2020; 384 Okba, Müller, Li, Wang, GeurtsvanKessel, Corman (CR17) 2020; 26 Petrilli, Jones, Yang, Rajagopalan, O’Donnell, Chernyak (CR3) 2020; 369 Helms, Tacquard, Severac, Leonard-Lorant, Ohana, Delabranche (CR2) 2020; 46 Zhang, Bastard, Liu, Le Pen, Moncada-Velez, Chen (CR5) 2020; 370 1168_CR23 Y Zhou (1168_CR19) 2020; 13 1168_CR22 DM Weinreich (1168_CR10) 2020; 384 AL Peters (1168_CR12) 2015; 170 SE Vazquez (1168_CR7) 2021; 41 CM Petrilli (1168_CR3) 2020; 369 J Helms (1168_CR2) 2020; 46 1168_CR20 VA Simonovich (1168_CR8) 2020; 384 RA Middelburg (1168_CR13) 2010; 50 C Huang (1168_CR1) 2020; 395 CH GeurtsvanKessel (1168_CR16) 2020; 11 P Chen (1168_CR11) 2020; 384 NMA Okba (1168_CR17) 2020; 26 J Hadjadj (1168_CR4) 2020; 369 1168_CR6 Q Zhang (1168_CR5) 2020; 370 1168_CR9 JC Marshall (1168_CR14) 2020; 20 1168_CR15 1168_CR18 T Jun (1168_CR21) 2021; 1
References_xml	– ident: CR22 – volume: 170 start-page: 597 issue: 5 year: 2015 end-page: 614 ident: CR12 article-title: Antibody-mediated transfusion-related acute lung injury; from discovery to prevention publication-title: Br J Haematol doi: 10.1111/bjh.13459 – volume: 384 start-page: 619 issue: 7 year: 2020 end-page: 629 ident: CR8 article-title: A randomized trial of convalescent plasma in Covid-19 severe pneumonia publication-title: N Engl J Med doi: 10.1056/NEJMoa2031304 – ident: CR18 – volume: 369 start-page: 718 issue: 6504 year: 2020 end-page: 724 ident: CR4 article-title: Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients publication-title: Science (New York, NY) doi: 10.1126/science.abc6027 – volume: 13 start-page: 1077 issue: 6 year: 2020 end-page: 1086 ident: CR19 article-title: Clinical and autoimmune characteristics of severe and critical cases of COVID-19 publication-title: Clin Transl Sci doi: 10.1111/cts.12805 – ident: CR15 – volume: 370 start-page: eabd4570 issue: 6515 year: 2020 ident: CR5 article-title: Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 publication-title: Science (New York, NY) doi: 10.1126/science.abd4570 – volume: 384 start-page: 238 issue: 3 year: 2020 end-page: 251 ident: CR10 article-title: REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2035002 – ident: CR9 – volume: 41 start-page: 1169 issue: 6 year: 2021 end-page: 1171 ident: CR7 article-title: Neutralizing autoantibodies to type I interferons in COVID-19 convalescent donor plasma publication-title: J Clin Immunol doi: 10.1007/s10875-021-01060-0 – volume: 11 start-page: 3436 issue: 1 year: 2020 ident: CR16 article-title: An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment publication-title: Nat Commun doi: 10.1038/s41467-020-17317-y – volume: 1 start-page: 3 issue: 1 year: 2021 ident: CR21 article-title: Analysis of sex-specific risk factors and clinical outcomes in COVID-19 publication-title: Commun Med doi: 10.1038/s43856-021-00006-2 – ident: CR6 – volume: 20 start-page: e192 issue: 8 year: 2020 end-page: e197 ident: CR14 article-title: A minimal common outcome measure set for COVID-19 clinical research publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(20)30483-7 – volume: 369 start-page: m1966 year: 2020 ident: CR3 article-title: Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study publication-title: Bmj doi: 10.1136/bmj.m1966 – volume: 395 start-page: 497 issue: 10223 year: 2020 end-page: 506 ident: CR1 article-title: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China publication-title: Lancet doi: 10.1016/S0140-6736(20)30183-5 – volume: 50 start-page: 2447 issue: 11 year: 2010 end-page: 2454 ident: CR13 article-title: Female donors and transfusion-related acute lung injury: a case-referent study from the International TRALI Unisex Research Group publication-title: Transfusion doi: 10.1111/j.1537-2995.2010.02715.x – volume: 26 start-page: 1478 issue: 7 year: 2020 end-page: 1488 ident: CR17 article-title: Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients publication-title: Emerg Infect Dis doi: 10.3201/eid2607.200841 – ident: CR23 – volume: 384 start-page: 229 issue: 3 year: 2020 end-page: 237 ident: CR11 article-title: SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19 publication-title: N Engl J Med doi: 10.1056/NEJMoa2029849 – ident: CR20 – volume: 46 start-page: 1089 issue: 6 year: 2020 end-page: 1098 ident: CR2 article-title: High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study publication-title: Intensive Care Med doi: 10.1007/s00134-020-06062-x – ident: 1168_CR15 doi: 10.7554/eLife.64508 – ident: 1168_CR6 doi: 10.1126/science.abd4585 – volume: 13 start-page: 1077 issue: 6 year: 2020 ident: 1168_CR19 publication-title: Clin Transl Sci doi: 10.1111/cts.12805 – volume: 369 start-page: m1966 year: 2020 ident: 1168_CR3 publication-title: Bmj doi: 10.1136/bmj.m1966 – ident: 1168_CR23 doi: 10.1084/jem.20202486 – volume: 384 start-page: 619 issue: 7 year: 2020 ident: 1168_CR8 publication-title: N Engl J Med doi: 10.1056/NEJMoa2031304 – volume: 1 start-page: 3 issue: 1 year: 2021 ident: 1168_CR21 publication-title: Commun Med doi: 10.1038/s43856-021-00006-2 – volume: 384 start-page: 238 issue: 3 year: 2020 ident: 1168_CR10 publication-title: N Engl J Med doi: 10.1056/NEJMoa2035002 – volume: 384 start-page: 229 issue: 3 year: 2020 ident: 1168_CR11 publication-title: N Engl J Med doi: 10.1056/NEJMoa2029849 – volume: 26 start-page: 1478 issue: 7 year: 2020 ident: 1168_CR17 publication-title: Emerg Infect Dis doi: 10.3201/eid2607.200841 – ident: 1168_CR22 doi: 10.1126/sciimmunol.abl4340 – volume: 370 start-page: eabd4570 issue: 6515 year: 2020 ident: 1168_CR5 publication-title: Science (New York, NY) doi: 10.1126/science.abd4570 – volume: 50 start-page: 2447 issue: 11 year: 2010 ident: 1168_CR13 publication-title: Transfusion doi: 10.1111/j.1537-2995.2010.02715.x – volume: 170 start-page: 597 issue: 5 year: 2015 ident: 1168_CR12 publication-title: Br J Haematol doi: 10.1111/bjh.13459 – volume: 46 start-page: 1089 issue: 6 year: 2020 ident: 1168_CR2 publication-title: Intensive Care Med doi: 10.1007/s00134-020-06062-x – volume: 11 start-page: 3436 issue: 1 year: 2020 ident: 1168_CR16 publication-title: Nat Commun doi: 10.1038/s41467-020-17317-y – volume: 395 start-page: 497 issue: 10223 year: 2020 ident: 1168_CR1 publication-title: Lancet doi: 10.1016/S0140-6736(20)30183-5 – ident: 1168_CR18 doi: 10.1101/2020.12.10.20247205 – volume: 41 start-page: 1169 issue: 6 year: 2021 ident: 1168_CR7 publication-title: J Clin Immunol doi: 10.1007/s10875-021-01060-0 – ident: 1168_CR9 doi: 10.21203/rs.3.rs-105265/v1 – volume: 369 start-page: 718 issue: 6504 year: 2020 ident: 1168_CR4 publication-title: Science (New York, NY) doi: 10.1126/science.abc6027 – ident: 1168_CR20 doi: 10.1007/s00134-021-06392-4 – volume: 20 start-page: e192 issue: 8 year: 2020 ident: 1168_CR14 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(20)30483-7
SSID	ssj0003625
Score	2.4925191
Snippet	Purpose To study the effect of interferon-α2 auto-antibodies (IFN-α2 Abs) on clinical and virological outcomes in critically ill COVID-19 patients and the risk... To study the effect of interferon-α2 auto-antibodies (IFN-α2 Abs) on clinical and virological outcomes in critically ill COVID-19 patients and the risk of... Abstract PurposeTo study the effect of interferon-α2 auto-antibodies (IFN-α2 Abs) on clinical and virological outcomes in critically ill COVID-19 patients and...
SourceID	pubmedcentral proquest pubmed crossref springer
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	232
SubjectTerms	Adult Aged Antibodies, Neutralizing - immunology Antibodies, Viral - immunology Antiviral Agents - immunology Autoantibodies Autoantibodies - immunology Biomedical and Life Sciences Biomedicine Blood Component Transfusion - methods Coronaviruses COVID-19 COVID-19 - immunology COVID-19 - therapy COVID-19 Serotherapy Critical Illness Enzyme-linked immunosorbent assay Female Humans Immunization, Passive - methods Immunoglobulin G - immunology Immunology Infectious Diseases Interferon Interferon alpha-2 - immunology Internal Medicine Male Medical Microbiology Middle Aged Original Original Article Patients Plasma Plasma - immunology Respiratory diseases Respiratory tract SARS-CoV-2 - immunology
SummonAdditionalLinks	– databaseName: Biological Science Database dbid: M7P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Jb9QwFH6CghAX9iVQkJG4gUXieLycUDVQAYIyh4J6ixwv6kiQlFn4X_wRfhPPjiejoaIXznEUO2_x93aA520QlklT0tAGR3l0NLVSeuqDUi4oYyd1KhT-KI-O1MmJnmWH2zKnVW50YlLUrrfRR_6KIfKuYlKifn32g8apUTG6mkdoXIYrsUtCnVL3ZqMmRuWcUhiZrFCoOctFM7l0DpE6jQkKMRShaL17MZ1Dm-eTJv-KnKYL6fDm_x7lFtzIUJQcDLxzGy757g5c-5SD7XfhQ_IWBr_oO_r7FyMH61VPkRDzto-ph2TekWnfIacOHaHIDIH4d0OOhz4FBNEwmX7--v4NrfQ9-HL49nj6jubRC9QihFtRWYaayeC49nVpNAs8hmiFdmiyea25sMJ4bnVp0aJxQvDSsIlziLacUEFX9X3Y6_rOPwRinWGt5ghMLOPWoH3HTRDKhEqHyipWQLX5743NfcnjeIxvzbajcqRVg7RqEq2auoAX4ztnQ1eOC1fvb-jQZAldNlsiFPBsfIyyFQMmpvP9GtdEa0sjoMZNPhioP36u5lJItM4KkDt8MS6Ifbt3n3Tz09S_W02UUHVZwMsNB2239e9TPLr4FI_hOouVGSmhfB_2Vou1fwJX7c_VfLl4muTiDyxVEds priority: 102 providerName: ProQuest
Title	Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19
URI	https://link.springer.com/article/10.1007/s10875-021-01168-3 https://www.ncbi.nlm.nih.gov/pubmed/34767118 https://www.proquest.com/docview/2626114109 https://www.proquest.com/docview/2597490202 https://pubmed.ncbi.nlm.nih.gov/PMC8586830
Volume	42
WOSCitedRecordID	wos000717931900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1573-2592 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0003625 issn: 0271-9142 databaseCode: RSV dateStart: 19970101 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB7RFqFeeFMCZRUkbmApcbx-HMvSChAsq1KqvUWOH2IlSNA--F_8EX4TY-dRlgISXHLxJLHHM_aM55sxwJPKc0OFzoivvCUsHDRVQjjivJTWS23GRUwUfiOmUzmfq1mXFLbq0e59SDKu1D8lu6FtTQKkIAQPJCl2YA-3OxnU8fT9-bD-4pIcgYtU5KjKjHapMr__xvZ2dMnGvAyV_CVeGrehkxv_N4CbcL0zO9OjVk5uwRVX34Zrb7vA-h14HU8GvVs2Nfn-jaZHm3VDkOmLqgkww3RRp5OmRqlsqz-lMzS6P-v0rK1JkKLlm07enb96QXJ1Fz6cHJ9NXpLumgVi0FxbE5H5ggpvmXJFphX1LIRjubLonjmlGDdcO2ZUZtB7sZyzTNOxtWhZWS69yot7sFs3tbsPqbGaVorhrBjKjEZfjmnPpfa58rmRNIG853Zpuhrk4SqMT-VF9eTApBKZVEYmlUUCT4d3vrQVOP5KfdhPYtlp46qk6LXlAdCqEng8NKMeheCIrl2zQZrgWSk0nrGTB-2cD78rmOACPbEExJY0DAShRvd2S734GGt1y7HkssgSeNbLxEW3_jyKB_9G_hD2acjKiGDyQ9hdLzfuEVw1X9eL1XIEO2Iu4lPiU07yEew9P57OTkcB6DobRe35AdFwDRw
linkProvider	Springer Nature
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgigX3o9AASPBiVokjjexDwhVW6ou3S57WFBvwXFsdSVIyj5A_Ckk_gi_ibHzWC0VvfXAOc7D8efxN55vxgDPc5tolqqQ2twWlLuNpjxNDTVWiMIKpXuxTxQepqOROD6W4w342ebCOFllaxO9oS4q7fbIXzFk3pETJco3p1-pOzXKRVfbIzRqWByaH9_RZZu_Huzh-L5gbP_tpH9Am1MFqEZ2sqBpaGOW2oJLE4dKMstd9DGRBXojRkqe6EQZrmWokawXScJDxXpFgUSiSISVUYzPvQSXkUYw4aWC487y42LgJZMsjdCIcNYk6TSpeugZUCeIcKEPQeP1hfAMuz0r0vwrUusXwP0b_9uvuwnXG6pNduu5cQs2THkbrh41YoI78M7vhlozq0r6-xcju8tFRRFo07xy0koyLUm_KnEm1hWvyBgdjS-KTOo6DATZPum__zjYo5G8Cx8upCf3YLOsSvMAiC4UyyVH4qUZ1wr9V65sIpSNpI20YAFE7Thnuqm77o7_-JytKkY7bGSIjcxjI4sDeNndc1pXHTm39XY77lljgebZatADeNZdRtvhAkKqNNUS2zhvUqLDgB95v0Zb97qYp0mK3mcA6RoOuwauLvn6lXJ64uuTi55IRBwGsNMidvVZ_-7Fw_N78RS2DiZHw2w4GB0-gmvMZaF48fw2bC5mS_MYruhvi-l89sTPSQKfLhrJfwCyuGvq
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6VgiouvB-BAkaCE1hNHG9sHxCqdlmxtCx7KKi34PghVoKk7APEz-LKj-A3Mc5jV0tFbz1wjvNw_Hk8n-ebMcCTwmeGCR1TX3hLedhoKoRw1HkprZfa9NI6UfhQjMfy-FhNtuBXlwsTZJWdTawNta1M2CPfY-h5J0GUqPZ8K4uYDIYvT77ScIJUiLR2x2k0EDlwP74jfZu_GA1wrJ8yNnx11H9N2xMGqEFPZUFF7FMmvOXKpbFWzPMQicyURWbilOKZybTjRsUGHXebZTzWrGctOhU2k14lKT73AlwUKaI4ZKn31_ISXBhq-SQTCRoUztqEnTZtD1kCDeKIEAaRNN1cFE95uqcFm39FbevFcHj1f_6N1-BK64KT_WbOXIctV96AnbetyOAmvKl3Sb2bVSX9_ZOR_eWiogjAaVEFySWZlqRflThDm0pYZIIE5IsmR019BoIsgPTffRgNaKJuwftz6clt2C6r0t0FYqxmheLokBnGjUZey7XPpPaJ8omRLIKkG_PctPXYw7Egn_N1JemAkxxxktc4ydMInq3uOWmqkZzZerfDQN5apnm-BkAEj1eX0aaEQJEuXbXENoFlKiQS-JF3GuStXpdykQlkpRGIDUyuGoR65ZtXyumnum657MlMpnEEzzv0rj_r3724d3YvHsEOAjg_HI0P7sNlFpJTak39LmwvZkv3AC6Zb4vpfPawnp4EPp43kP8Aa9B0YA
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Interferon-%CE%B12+Auto-antibodies+in+Convalescent+Plasma+Therapy+for+COVID-19&rft.jtitle=Journal+of+clinical+immunology&rft.au=Raadsen%2C+Matthijs+P&rft.au=Gharbharan%2C+Arvind&rft.au=Jordans%2C+Carlijn+C+E&rft.au=Mykytyn%2C+Anna+Z&rft.date=2022-02-01&rft.issn=1573-2592&rft.eissn=1573-2592&rft.volume=42&rft.issue=2&rft.spage=232&rft_id=info:doi/10.1007%2Fs10875-021-01168-3&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0271-9142&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0271-9142&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0271-9142&client=summon